Detalhe da pesquisa
1.
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Int Immunopharmacol
; 134: 112192, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38761778
2.
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates.
NPJ Vaccines
; 7(1): 105, 2022 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056015